Download MendeleyReplacing the phthalimide core in thalidomide with benzotriazole.
Krasavin, M., Bubyrev, A., Kazantsev, A., Heim, C., Maiwald, S., Zhukovsky, D., Dar'in, D., Hartmann, M.D., Bunev, A.(2022) J Enzyme Inhib Med Chem 37: 527-530
- PubMed: 35220840
- DOI: https://doi.org/10.1080/14756366.2021.2024525
- Primary Citation of Related Structures:
7PJK - PubMed Abstract:
The advent of proteolysis-targeting chimaeras (PROTACs) mandates that new ligands for the recruitment of E3 ligases are discovered. The traditional immunomodulatory drugs (IMiDs) such as thalidomide and its analogues (all based on the phthalimide glutarimide core) bind to Cereblon, the substrate receptor of the CRL4A CRBN E3 ligase. We designed a thalidomide analogue in which the phthalimide moiety was replaced with benzotriazole, using an innovative synthesis strategy. Compared to thalidomide, the resulting "benzotriazolo thalidomide" has a similar binding mode, but improved properties, as revealed in crystallographic analyses, affinity assays and cell culture.
Organizational Affiliation:
Institute of Chemistry, Saint Petersburg State University, Saint Petersburg, Russia.
